The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells

Journal of the American Society of Nephrology

Volumn 10, Issue 1 SUPPL. 11, 1999, Pages

  Vauquelin, Georges ^a   Fierens, Frederik L P ^a   De Backer, Jean Paul ^a   Vanderheyden, Patrick M L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; INOSITOL PHOSPHATE;

ANIMAL CELL; ARTICLE; CHO CELL; DOSE RESPONSE; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR CLONING; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

EID: 0032929523     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Zhang JC, Van Meel A, Pfaffendorf M, Van Zwieten P: Different types of angiotensin II receptor antagonism induced by BIBS 222 in the rat portal vein and rabbit aorta: The influence of receptor reserve. J Pharmacol Exp Ther 269: 509-514, 1993
2. Mochizuki S, Sato T, Furata K, Hase K, Ohkura Y, Fukai C, Kosakai K, Wakabayashi S, Tomiyama A: Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol 25: 22-29, 1995
3. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K: Inhibition of rabbit aoritc angiotensin n (AII) receptor by CV-11974, a new neuropeptide AII antagonist. Biochem Pharmacol 46: 311-318, 1993
4. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 319: 137-146, 1997
5. Dickinson KE, Cohen RB, Skwish S, Delaney CL, Serafino RP, Poss MA, Gu Z, Ryono DE, Moreland S, Powell JR: BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174. Br J Pharmacol 113: 179-189, 1994
6. Panek RL, Lu GH, Overhisser RW, Major TC, Hodges JC, Taylor DG: Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther 273: 753-761, 1995
7. Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW: Non-peptide angiotensin agonist: Functional and molecular interaction with the AT1 receptor. J Biol Chem 270: 1493-1496, 1995
8. Seeuwen K, Lagarde A, Pouysségur J: Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C. EMBO J 7: 161-168, 1998
9. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF: Non-peptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12: 55-62, 1991
10. de Chaffoy de Courcelles D, Leysen JE, Roevens P, Van Belle H: The serotonin-S2 receptor: A receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Dev Res 8: 173-178, 1986
11. Robertson MJ, Dougall IG, Harper D, Mckechnie KCW, Leff P: Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model. Trends Pharmacol Sci 15: 364-369, 1994
12. Robertson MJ, Barnes JC, Drew GM, Clark KL, Marshall FH, Michel A, Middlemiss D, Ross BC, Scopes D, Dowle MD: Pharmacological profile of GR 117289 in vitro: A novel, potent, and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol 107: 1173-1180, 1992
13. Gero A: Desensitization, two-state receptors and pharmacologi-cal parameters. J Theoret Biol 103: 137-161, 1983
14. Liu YJ, Shankley NP, Welsh NJ, Black JW: Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action. Br J Pharmacol 106: 233-241, 1992